Affimed (NASDAQ:AFMD) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

AFMD has been the topic of several other research reports. Jefferies Financial Group raised shares of Affimed from a “hold” rating to a “buy” rating and increased their target price for the company from $1.80 to $4.00 in a report on Tuesday. ValuEngine raised shares of Affimed from a “buy” rating to a “strong-buy” rating in a report on Tuesday. BMO Capital Markets increased their target price on shares of Affimed from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Zacks Investment Research raised shares of Affimed from a “sell” rating to a “hold” rating in a report on Friday, June 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $3.75.

AFMD stock opened at $5.30 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36. Affimed has a 52 week low of $1.15 and a 52 week high of $7.35. The firm has a market cap of $346.27 million, a P/E ratio of -6.79 and a beta of 2.35.

Hedge funds have recently added to or reduced their stakes in the stock. Stanley Laman Group Ltd. bought a new position in shares of Affimed during the 2nd quarter valued at $100,000. Barclays PLC grew its holdings in shares of Affimed by 385.3% during the 1st quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 51,573 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Affimed during the 2nd quarter valued at $165,000. DRW Securities LLC bought a new stake in Affimed in the 1st quarter worth $204,000. Finally, Sofinnova Ventures Inc bought a new stake in Affimed in the 1st quarter worth $205,000. 41.11% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Read More: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.